Boundless Bio, Inc. (BOLD)

Current Report Filed: 2026-05-08

Boundless Bio announced Q1 2026 financial results on May 8, 2026, but the actual press release content with specific financial metrics is not included in this 8-K filing, limiting visibility into revenue, expenses, and operational performance.
The company is classified as an emerging growth company, which provides certain regulatory relief and exemptions from compliance requirements, suggesting it is still in a relatively early stage of development.
The filing is a standard 8-K disclosure under Item 2.02 (Results of Operations and Financial Condition) with no material agreements, leadership changes, or other significant events reported, indicating routine quarterly earnings announcement.

Quarterly Report Filed: 2026-05-08

The filing appears incomplete or truncated, with only XML metadata tags visible and no substantive financial data, operational results, or management discussion provided for meaningful Q1 2026 analysis.
Multiple subsequent events are referenced (April 13, 2026 and April 17, 2026) suggesting recent material activities including a new lease obligation (TwoZeroTwoSixLeaseMember), but details are not disclosed in the provided excerpt.
The company maintains various equity incentive programs and an open market sale agreement with shares reserved for issuance, indicating ongoing capital allocation activities and potential for shareholder dilution.

Current Report Filed: 2026-04-13

Boundless Bio has terminated its lease agreement for its laboratory and office space in San Diego, California, effective May 31, 2026, which was originally set to expire on October 31, 2034.
The company has agreed to pay a $10 million lease modification payment and forfeit its $0.5 million security deposit as part of the lease termination agreement.
The termination of the lease agreement is subject to the landlord successfully leasing the premises to a new tenant, which has been satisfied.

Current Report Filed: 2026-03-09

Boundless Bio, Inc. reported its Q4 2025 and full-year 2025 financial results, showing continued growth and progress in its operations.
The company announced the resignation of Christine Brennan, Ph.D. from its Board of Directors, citing her acceptance of a new role at Johnson & Johnson Development Corporation.
The resignation of Dr. Brennan does not appear to be due to any disagreement with the company, suggesting an amicable departure.

Annual Report Filed: 2026-03-09

The filing indicates Boundless Bio, Inc. (BOLD) has experienced growth in its research and development expenses over the past two fiscal years, which could signal increased investment in its product pipeline.
Boundless Bio has a significant amount of cash, cash equivalents, and short-term investments on its balance sheet as of the end of the latest fiscal year, suggesting a strong liquidity position.
The company has an open market sale agreement in place, which could provide additional funding if utilized, but also represents a potential dilution risk for shareholders.

Insider Trading Filed: 2026-01-26

David A. Hinkle, the Senior VP, Finance, Controller and Treasurer of Boundless Bio, Inc. (BOLD), has been granted a stock option to acquire 140,000 shares of the company's common stock.
The stock option has an exercise price of $1.26 and vests in 48 substantially equal monthly installments, with the first vesting on February 1, 2026.
This insider transaction suggests that Hinkle is confident in the company's future and aligns his interests with those of shareholders through this equity-based compensation.

Insider Trading Filed: 2026-01-26

Zachary Hornby, the President and CEO of Boundless Bio, Inc., has been granted a stock option to acquire 600,000 shares of the company's common stock at an exercise price of $1.26 per share. This indicates management confidence in the company's future prospects.
The stock option vests over a 4-year period, with 1/48th of the shares vesting monthly, aligning Hornby's incentives with long-term shareholder value creation.
The filing does not indicate any other significant changes in Hornby's beneficial ownership, suggesting a stable leadership team and ownership structure.

Insider Trading Filed: 2026-01-26

Robert Doebele, the Chief Medical Officer of Boundless Bio, Inc. (BOLD), was granted a stock option to acquire 230,000 shares of the company's common stock on January 23, 2026.
The stock option has an exercise price of $1.26 per share and vests in 48 substantially equal monthly installments, with the first tranche vesting on February 1, 2026.
This stock option grant indicates the company's commitment to incentivizing and retaining its key executive talent, which is a positive sign for the company's long-term growth and success.

Insider Trading Filed: 2026-01-26

Christian Hassig, the Chief Scientific Officer of Boundless Bio, Inc., has been granted 230,000 stock options with an exercise price of $1.26 per share, vesting over 48 months.
The stock options were granted on January 23, 2026, indicating continued confidence in the company's leadership and long-term growth prospects.
The significant size of the stock option grant suggests Hassig's important role and influence within the company as a key executive.

Insider Trading Filed: 2026-01-26

The reporting person, Jessica Oien, was granted a stock option to purchase 220,000 shares of Boundless Bio, Inc. common stock at an exercise price of $1.26 per share, with a vesting period of 48 months.
This stock option award suggests that Oien, who holds the position of Chief Legal Officer and Corporate Secretary, has been granted an equity incentive as part of her compensation package to align her interests with those of the company and its shareholders.
The filing does not indicate any other transactions, such as open market purchases or sales of Boundless Bio shares, which could provide insights into Oien's overall investment thesis or sentiment towards the company.

Important Information